### PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1 Stylesheet Version v1.2 EPAS ID: PAT4543382

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT

#### **CONVEYING PARTY DATA**

Name	Execution Date
TEVA CZECH INDUSTRIES S.R.O.	08/07/2017

#### **RECEIVING PARTY DATA**

Name:	TEVA PHARMACEUTICALS INTERNATIONAL GMBH	
Street Address:	SCHLÜSSELSTRASSE 12	
City:	JONA	
State/Country:	SWITZERLAND	
Postal Code:	8645	

#### **PROPERTY NUMBERS Total: 1**

Property Type	Number
Application Number:	15625724

#### **CORRESPONDENCE DATA**

**Fax Number:** (206)682-6031

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent

using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

**Phone:** 2066224900

Email:carolw@seedip.comCorrespondent Name:CAROL J. ROTHAddress Line 1:701 FIFTH AVENUE

Address Line 2: SUITE 5400

Address Line 4: SEATTLE, WASHINGTON 98104-7092

ATTORNEY DOCKET NUMBER:	480329.402_6_OF_6
NAME OF SUBMITTER:	CAROL J. ROTH
SIGNATURE:	/Carol J. Roth/
DATE SIGNED:	08/09/2017

#### **Total Attachments: 5**

source=480329_402_Assign_6_of_6	_TCI_to_TEVA#page1.tif
source=480329_402_Assign_6_of_6	_TCI_to_TEVA#page2.tif
source=480329_402_Assign_6_of_6	_TCI_to_TEVA#page3.tif
source=480329_402_Assign_6_of_6	_TCI_to_TEVA#page4.tif
source=480329_402_Assign_6_of_6	_TCI_to_TEVA#page5.tif

PATENT 504496679 REEL: 043248 FRAME: 0767

#### ASSIGNMENT

WHEREAS, Teva Czech Industries s.r.o. (hereinafter referred to as ASSIGNOR), a Czech corporation having a place of business at Ostravska 29, Opava, Czech Republic 74770, is an assignee of record of the patent application entitled "SOLID STATE FORMS OF SPIRO-OXINDOLE COMPOUNDS," as described and claimed in the specification for which an application for United States letters patent was filed on June 16, 2017, and assigned Application No. 15/625,724; which application claims the benefit of U.S. Provisional Application No. 62/351,150, filed June 16, 2016; and for which an application was filed on June 16, 2017 with the U.S. Receiving Office of the PCT and assigned Application No. PCT/US2017/037979;

WHEREAS, Teva Pharmaceuticals International GmbH (hereinafter referred to as ASSIGNEE), a Switzerland corporation having a place of business at Schlüsselstrasse 12, Jona, Switzerland 8645, is desirous of acquiring the entire right, title and interest in and to the invention and in and to any letters patent that may be granted therefor in the United States and in any and all foreign countries;

NOW, THEREFORE, in exchange for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, ASSIGNOR hereby sells, assigns and transfers unto said ASSIGNEE, the entire right, title and interest in and to said invention, said application and any and all letters patent which may be granted for said invention in the United States of America and its territorial possessions including any extensions or adjustments in term thereof and in any and all foreign countries, and in any and all divisions, reissues and continuations thereof, including the right to file foreign applications directly in the name of ASSIGNEE and to claim priority rights deriving from said United States application to which said foreign applications are entitled by virtue of international convention, treaty or otherwise, and including the right to sue and collect damages for past and present infringement of said letters patent; said invention, application and all letters patent on said invention to be held and enjoyed by ASSIGNEE and its successors and assigns for their use and benefit and of their successors and assigns as fully and entirely as the same would have been held and enjoyed by ASSIGNOR had this assignment, transfer and sale not been made. ASSIGNOR hereby authorizes and requests the Commissioner of Patents and Trademarks to issue all letters patent on said invention to ASSIGNEE. ASSIGNOR agrees to execute all instruments and documents required for the making and prosecution of applications for United States and foreign letters patent on said invention, for litigation regarding said letters patent, or for the purpose of protecting title to said invention or letters patent therefor.

This Assignment is effective as of June 16, 2016.

# 

**ASSIGNOR SIGNATURE:** 

#### **ASSIGNOR SIGNATURE:**

Teva Czech Industries s.r.o,
Ву;
Printed Name: Richard Szrajber
Title:Director
Date; 8.8.2017
STATEMENT AND SIGNATURE OF WITNESS:
, LUCIE NURCAKOVA , whose full address is:
Name of Witness  OPAVA 6 HLAVNI 201
Address of Witness
was personally present and did see Richard Szrajber execute this Assignment on the
day of <u>AUGUST</u> , 2017, and such Assignor is personally known
o me to be the person described herein.
Signature of Witness
Signatúre of Witness

## 

ASSIGNEE SIGNATURE:
By: Blund How
Printed Name: David Koch
Title: Managing Officer
Date: 20 July 2017
,
STATEMENT AND SIGNATURE OF WITNESS:
I, DANA STEPINA , whose full address is:
Name of Witness <u>UIA SAJ ROLJATURE F, 6902 PARADISO, SWITZERLAND,</u> Address of Witness
was personally present and did see David Koch execute this Assignment on the
day of <u>FUCY</u> , 2017, and such Assignor is personally known
to me to be the person described herein.
hu
Signature of Witness
(480329.402) 5602871_1

Page 5 of 5